Gsa Capital Partners LLP Red Hill Biopharma Ltd. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$0.63 - $2.58 $10,425 - $42,693	16,548 New	16,548 $14,000
Q1 2022 May 11, 2022	SELL	$1.65 - $3.12 $360,257 - $681,214	-218,338 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.31 - $5.85 $262,379 - $664,466	113,584 Added 108.43%	218,338 $563,000
Q3 2021 Nov 12, 2021	BUY	$4.55 - $10.36 $104,540 - $238,031	22,976 Added 28.1%	104,754 $480,000
Q2 2021 Aug 05, 2021	BUY	$5.98 - $7.51 $380,489 - $477,838	63,627 Added 350.54%	81,778 $563,000
Q1 2021 May 10, 2021	SELL	$6.98 - $11.29 $184,390 - $298,247	-26,417 Reduced 59.27%	18,151 $133,000
Q4 2020 Feb 03, 2021	BUY	$7.81 - $10.39 $348,076 - $463,061	44,568 New	44,568 $360,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $557M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.